The University of Notre Dame Australia’s Institute for Health Research (IHR) and MGC Pharma have announced publication of the study protocol for a clinical trial evaluating medical cannabis use with patients with dementia.
The trial was registered in the Australian and New Zealand Clinical Trial Register (ANZCTR) earlier this week. The research project, which we again recently mentioned here on Hemp Gazette, will delve into the effects of medicinal cannabis oil among those living in a residential aged care facility medically diagnosed with dementia.
The trial involves an N-of-1, randomised double blind trial cross-over approach with those participating receiving either an oil-based placebo or medical cannabis oil containing THC and CBD. The trial aims to monitor the effects of administering the oil and to determine if there are any changes in behaviour, quality of life, discomfort or pain levels or weight.
The primary question the study is seeking to answer is: